Galapagos NV (GLPG) IPO Opens up 10%

Bryan, Garnier & Co Announces the Successful $275m IPO for Galapagos NV, the Largest Nasdaq IPO of European Biotech

LONDON, May 14, 2015 /PRNewswire/ --

Bryan, Garnier & Co, the pan-European investment bank for growth companies, announces the successful $275 million Nasdaq IPO for Galapagos NV, a major European clinical-stage biotechnology company. Bryan, Garnier & Co is the only European investment bank in the IPO syndicate. The Galapagos IPO on Nasdaq confirms the strong momentum of the European healthcare sector.

     (Logo: http://photos.prnewswire.com/prnh/20150514/744149 )... More

Galapagos (Nasdaq: GLPG) to Ring The Nasdaq Stock Market Opening Bell

ADVISORY, May 14, 2015 (GLOBE NEWSWIRE) --

What: 

Galapagos (Nasdaq: GLPG) (Euronext: GLPG) is a clinical-stage European biotechnology company specialized in the discovery and development of small molecule medicines with novel modes of action.  Galapagos has just reported positive Phase 2B research results with filgotinib, a new oral medicine for rheumatoid arthritis which is partnered with AbbVie.  Galapagos will visit the Nasdaq MarketSite in Times Square in celebration of its IPO on The Nasdaq Stock Market to raise funds... More

Galapagos raises $275 million gross proceeds with NASDAQ IPO

MECHELEN, Belgium, May 13, 2015 (GLOBE NEWSWIRE) -- Galapagos NV (Euronext: GLPG) announced today the pricing of its global offering totaling $275 million gross proceeds of 6,550,000 new ordinary shares, consisting of 4,996,522 American Depositary Shares ("ADSs") at $42.05 per ADS, and 1,533,478 ordinary shares at a price of 37.00 per share, both before underwriting discounts. These shares were placed in a concurrent public offering in the US and private placement in Europe (together the "global offering"). The price per ADS was based on 37.00 per ordinary share at an exchange rate of $1.1365 per Euro.

... More